The long-acting integrase inhibitor GSK744 protects macaques from repeated intravaginal SHIV challenge

Jessica Ann Radzio-Basu, William Spreen, Yun Lan Yueh, James Mitchell, Leecresia Jenkins, J. Gerardo García-Lerma, Walid Heneine

Research output: Contribution to journalArticle

43 Citations (Scopus)

Abstract

Daily preexposure prophylaxis (PrEP) with Truvada is a proven HIV prevention strategy; however, its effectiveness is limited by low adherence. Antiretroviral drug formulations that require infrequent dosing may increase adherence and thus PrEP effectiveness. We investigated whether monthly injections of a long-acting formulation of the HIV integrase inhibitor GSK1265744 (GSK744 LA) prevented simian/human immunodeficiency virus (SHIV) infection by vaginal challenge inmacaques. Female pigtailmacaques (n = 12) were exposed to intravaginal inoculations of SHIV twice a week for up to 11 weeks. Half of the animals received a GSK744 LA injection every 4 weeks, and half received placebo. GSK744 LA, at plasma concentrations achievablewith quarterly injections in humans, protected all six macaques from infection. Placebo controls were all infected after a median of 4 (range, 2 to 20) vaginal challenges with SHIV. Efficacy was related to high and sustained vaginal and plasma drug concentrations that remained above the protein-adjusted 90% inhibitory concentration during the dosing cycles. These data support advancement of GSK744 LA as a potential PrEP candidate for women.

Original languageEnglish (US)
Article number270ra5
JournalScience Translational Medicine
Volume7
Issue number270
DOIs
StatePublished - Jan 14 2015

Fingerprint

Integrase Inhibitors
Simian Immunodeficiency Virus
Macaca
HIV
Injections
HIV Integrase Inhibitors
Placebos
Drug Compounding
Virus Diseases
GSK1265744
Infection
Pharmaceutical Preparations
Proteins

All Science Journal Classification (ASJC) codes

  • Medicine(all)

Cite this

Radzio-Basu, Jessica Ann ; Spreen, William ; Yueh, Yun Lan ; Mitchell, James ; Jenkins, Leecresia ; García-Lerma, J. Gerardo ; Heneine, Walid. / The long-acting integrase inhibitor GSK744 protects macaques from repeated intravaginal SHIV challenge. In: Science Translational Medicine. 2015 ; Vol. 7, No. 270.
@article{26e1796da0634e53b8ae980fc4eea03b,
title = "The long-acting integrase inhibitor GSK744 protects macaques from repeated intravaginal SHIV challenge",
abstract = "Daily preexposure prophylaxis (PrEP) with Truvada is a proven HIV prevention strategy; however, its effectiveness is limited by low adherence. Antiretroviral drug formulations that require infrequent dosing may increase adherence and thus PrEP effectiveness. We investigated whether monthly injections of a long-acting formulation of the HIV integrase inhibitor GSK1265744 (GSK744 LA) prevented simian/human immunodeficiency virus (SHIV) infection by vaginal challenge inmacaques. Female pigtailmacaques (n = 12) were exposed to intravaginal inoculations of SHIV twice a week for up to 11 weeks. Half of the animals received a GSK744 LA injection every 4 weeks, and half received placebo. GSK744 LA, at plasma concentrations achievablewith quarterly injections in humans, protected all six macaques from infection. Placebo controls were all infected after a median of 4 (range, 2 to 20) vaginal challenges with SHIV. Efficacy was related to high and sustained vaginal and plasma drug concentrations that remained above the protein-adjusted 90{\%} inhibitory concentration during the dosing cycles. These data support advancement of GSK744 LA as a potential PrEP candidate for women.",
author = "Radzio-Basu, {Jessica Ann} and William Spreen and Yueh, {Yun Lan} and James Mitchell and Leecresia Jenkins and Garc{\'i}a-Lerma, {J. Gerardo} and Walid Heneine",
year = "2015",
month = "1",
day = "14",
doi = "10.1126/scitranslmed.3010297",
language = "English (US)",
volume = "7",
journal = "Science Translational Medicine",
issn = "1946-6234",
publisher = "American Association for the Advancement of Science",
number = "270",

}

The long-acting integrase inhibitor GSK744 protects macaques from repeated intravaginal SHIV challenge. / Radzio-Basu, Jessica Ann; Spreen, William; Yueh, Yun Lan; Mitchell, James; Jenkins, Leecresia; García-Lerma, J. Gerardo; Heneine, Walid.

In: Science Translational Medicine, Vol. 7, No. 270, 270ra5, 14.01.2015.

Research output: Contribution to journalArticle

TY - JOUR

T1 - The long-acting integrase inhibitor GSK744 protects macaques from repeated intravaginal SHIV challenge

AU - Radzio-Basu, Jessica Ann

AU - Spreen, William

AU - Yueh, Yun Lan

AU - Mitchell, James

AU - Jenkins, Leecresia

AU - García-Lerma, J. Gerardo

AU - Heneine, Walid

PY - 2015/1/14

Y1 - 2015/1/14

N2 - Daily preexposure prophylaxis (PrEP) with Truvada is a proven HIV prevention strategy; however, its effectiveness is limited by low adherence. Antiretroviral drug formulations that require infrequent dosing may increase adherence and thus PrEP effectiveness. We investigated whether monthly injections of a long-acting formulation of the HIV integrase inhibitor GSK1265744 (GSK744 LA) prevented simian/human immunodeficiency virus (SHIV) infection by vaginal challenge inmacaques. Female pigtailmacaques (n = 12) were exposed to intravaginal inoculations of SHIV twice a week for up to 11 weeks. Half of the animals received a GSK744 LA injection every 4 weeks, and half received placebo. GSK744 LA, at plasma concentrations achievablewith quarterly injections in humans, protected all six macaques from infection. Placebo controls were all infected after a median of 4 (range, 2 to 20) vaginal challenges with SHIV. Efficacy was related to high and sustained vaginal and plasma drug concentrations that remained above the protein-adjusted 90% inhibitory concentration during the dosing cycles. These data support advancement of GSK744 LA as a potential PrEP candidate for women.

AB - Daily preexposure prophylaxis (PrEP) with Truvada is a proven HIV prevention strategy; however, its effectiveness is limited by low adherence. Antiretroviral drug formulations that require infrequent dosing may increase adherence and thus PrEP effectiveness. We investigated whether monthly injections of a long-acting formulation of the HIV integrase inhibitor GSK1265744 (GSK744 LA) prevented simian/human immunodeficiency virus (SHIV) infection by vaginal challenge inmacaques. Female pigtailmacaques (n = 12) were exposed to intravaginal inoculations of SHIV twice a week for up to 11 weeks. Half of the animals received a GSK744 LA injection every 4 weeks, and half received placebo. GSK744 LA, at plasma concentrations achievablewith quarterly injections in humans, protected all six macaques from infection. Placebo controls were all infected after a median of 4 (range, 2 to 20) vaginal challenges with SHIV. Efficacy was related to high and sustained vaginal and plasma drug concentrations that remained above the protein-adjusted 90% inhibitory concentration during the dosing cycles. These data support advancement of GSK744 LA as a potential PrEP candidate for women.

UR - http://www.scopus.com/inward/record.url?scp=84921044609&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=84921044609&partnerID=8YFLogxK

U2 - 10.1126/scitranslmed.3010297

DO - 10.1126/scitranslmed.3010297

M3 - Article

C2 - 25589631

AN - SCOPUS:84921044609

VL - 7

JO - Science Translational Medicine

JF - Science Translational Medicine

SN - 1946-6234

IS - 270

M1 - 270ra5

ER -